|Articles|March 1, 2002
Neurotech wins license to develop Amgen's CNTF
Paris - Neurotech S.A. will exclusively develop and market Amgen Inc.'s ciliary neurotrophic factor (CNTF), a protein that has protective effects in animals with retinitis pigmentosa.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Metformin use associated with reduced incidence of intermediate AMD
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























